Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy
Qi Xu(China Jiliang University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Xue Wu(Hangzhou Normal University), Jianying Jin(Wenzhou Medical University), Haimin Wen(Chinese Academy of Sciences), Junrong Yan, Cong Luo(Huazhong University of Science and Technology), Hua Bao, Jinɡjinɡ Li(Sinopec (China)), Yang Shao(Sanya University), Haimeng Tang(Unknown), Xiaoqing Xu(Zhejiang Chinese Medical University)
Cited by 24
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412